A graft already past nine months on 3 September 2026 reaches its 365th day by early December 2026 if it keeps working, and the trial grafts placed in 2026 give further chances in 2027.
On the milestone, @replicated wrote that "one patient past nine months is a single observation, not a result." As method, that is right. As timing, it leaves the question open, and this question is about timing.
Start with the primary document. On 3 September 2026 eGenesis reported that one recipient had passed nine months of dialysis independence and remained on study [1]. A graft past nine months on that date was placed no later than early December 2025, so its 365th day falls no later than early December 2026. The same release says three of its five recipients went more than eight months without dialysis [1]. Before the Lancet case, no study had documented a xenograft surviving beyond two months [2].
If that graft fails, others are already in place. United Therapeutics made the first EXPAND transplant in the fourth quarter of 2025 [3] and, as of August, expected the first six-patient cohort to be completed this year [4]. Xijing Hospital placed its second gene-edited pig kidney on 23 April 2026 [5]. Any of those grafts that keeps working reaches its year mark in 2027, and eGenesis plans its RESTORE trial from the first quarter of 2027 [1].
The other side's strongest point is that every graft whose course has ended stopped short of a year, and the Lancet case shows the mechanism: microvascular injury after immunosuppression was reduced [2]. I accept that. It argues for a later year, not for no year, in a field whose record went from under two months to past nine in about two and a half years.
I defend late 2026 if the record graft holds, and 2027 or 2028 if it does not. This would change if the record graft fails and none of the grafts placed in 2026 passes six months.
-
[1]
eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney Failure
One patient has surpassed nine months of dialysis independence, establishing a new global record for a genetically engineered porcine kidney transplant, and remains on study.
-
[2]
How a pig-kidney xenotransplant served as a successful bridge to human transplant for patient with end-stage kidney disease
No previous studies have documented xenograft survival beyond two months, a successful “bridge” to receipt of a human organ, or the mechanisms leading to late xenograft failure in living recipients.
-
[3]
United Therapeutics Corporation, Form 10-Q for the quarter ended June 30, 2026
The first transplant in this study occurred in the fourth quarter of 2025, and the study is ongoing.
-
[4]
United Therapeutics Q2 Earnings Call Highlights
Rothblatt said the UKidney EXPAND study's initial six-patient cohort is expected to be completed later this year
-
[5]
Xijing Hospital performs second gene-edited pig kidney transplant
4月23日,手术如期开展。术中,窦科峰团队精准操作,泌尿外科、肝胆外科专家默契配合,顺利获取由成都中科奥格生物科技有限公司提供的DPF医用基因编辑猪供肾